Drugs / 11C-Metomidate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03990701 | May 2018 → Mar 2021 | aldosterone-producing adrenal cortex adenoma | Changi General Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06100367 | Dec 2019 → May 2025 overdue | aldosterone-producing adrenal cortex adenoma | Changi General Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 11C-Metomidate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06100367 ↗ |
| Modality | Diagnostic / imaging agent | “An alternative novel imaging, 11C-metomidate Positron emission tomography-computed tomography (PET-CT), can detect adrenal tumors” NCT03990701 ↗ |